Side-by-side · Research reference

IGF-1 LR3vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/58 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

IGF-1 LR3

Vesugen

Primary target

IGF-1 receptor (IGF-1R)McTavish 2009

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

No — exogenous IGF analogue bypasses GH-mediated regulation

Not applicable — does not operate via hormone axis

Origin

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

IGF-1 LR3

Vesugen

Research dose (animal models)

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

—

In vitro typical concentration

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

—

Half-maximal stimulation

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

—

Evidence basis

Animal / in vitro only

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Human use

Not FDA-approved; no published human trials

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

03Metabolic / Fat Loss Evidence

Parameter

IGF-1 LR3

Vesugen

Mechanism

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

—

Direct lipolytic evidence

Minimal — primarily anabolic/anti-apoptotic in literature

—

Atherosclerotic plaque effects

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

—

Human data

None published

—

04Side Effects & Safety

Parameter

IGF-1 LR3

Vesugen

Hypoglycemia risk

Theoretical — IGF-1 analogues can lower blood glucose

—

Excessive cell proliferation

Mitogenic signaling; theoretical tumor promotion risk

—

Telomerase activation

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

—

Oocyte degeneration

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

—

Unregulated anabolism

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

—

Unknown human safety profile

No published human trials; safety data absent

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

Vesugen

—

Relative Contraindications

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

IGF-1 LR3

Vesugen

1. Research use only

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Typical research route

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Reconstitution (research)

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Stability

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)